Collaboration Tests TRX518-Bavencio Combo in Phase 1/2 Trial of Solid Tumors

Collaboration Tests TRX518-Bavencio Combo in Phase 1/2 Trial of Solid Tumors
Leap Therapeutics is launching a Phase 1/2 clinical trial to test its immunotherapy TRX518 in combination with Bavencio (avelumab) and chemotherapy in advanced solid tumors, as part of a collaboration established with Merck KGaA and Pfizer — the two companies developing and commercializing Bavencio. The trial is expected to begin recruiting patients in the first quarter of 2019. “The combination of TRX518 with anti-PD-L1

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *